Answers are grounded in this paper and cite their sources.
The aim of this open-label, multicenter, randomized controlled study was to investigate whether the life cycle pharma (LCP)-tacrolimus compared with the extended-release (ER)-tacrolimus formulation results in a difference in the prevalence of posttransplant diabetes, hypertension and chronic kidney disease (CKD) at 12 mo after liver transplantation.
No takes yet. Share an insight, caveat, or question.
Mulder et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: